Author(s): Rohini R. Pujari, Deepti D. Bandawane

Email(s): rohinirpujari@gmail.com

DOI: 10.52711/0974-360X.2022.00176   

Address: Rohini R. Pujari1*, Deepti D. Bandawane2
1School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University Kothrud, Pune - 411038, Maharashtra, India.
2Department of Pharmacology, Modern College of Pharmacy, Yamunanagar, Nigdi, Pune - 412105, Maharashtra, India.
*Corresponding Author

Published In:   Volume - 15,      Issue - 3,     Year - 2022


ABSTRACT:
Hematological toxicity or pancytopenia produced by carboplatin chemotherapy tends to limit the clinical usage of carboplatin as a potent antineoplastic agent. The current investigation was aimed at evaluation of the protective activity of a plant phenolic acid i.e. 2-pyrocatechuic acid (2,3 dihyroxybenzoic acid) against hematological adverse effects induced by carboplatin in Wistar rats. Intraperitoneal injection carboplatin (35 mg/kg) for 6 days resulted in significant alterations in hematological parameters such as decreased red blood cell, hemoglobin, total leukocyte and differential leukocyte counts and increased eosinophil counts in rat blood indicating severe hematological toxicities. Pre and co-administration of 2-pyrocatechuic acid at the doses 10, 30 and 100 with CP significantly attenuated the altered hematological indices in a dose-dependent manner exhibiting its efficacy as a protective agent for the amelioration and prevention of hematological toxicities induced by carboplatin chemotherapy.


Cite this article:
Rohini R. Pujari, Deepti D. Bandawane. 2-Pyrocatechuic Acid Attenuates Carboplatin Induced Hematological Toxicities in Wistar Rats. Research Journal of Pharmacy and Technology. 2022; 15(3):1053-8. doi: 10.52711/0974-360X.2022.00176

Cite(Electronic):
Rohini R. Pujari, Deepti D. Bandawane. 2-Pyrocatechuic Acid Attenuates Carboplatin Induced Hematological Toxicities in Wistar Rats. Research Journal of Pharmacy and Technology. 2022; 15(3):1053-8. doi: 10.52711/0974-360X.2022.00176   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-3-19


REFERENCES:
1.    Testart-Paillet D, Girard P, You B, Freyer G, Pobel C, Tranchand B. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit Rev Oncol Hematol. 2007;63:1-11.
2.    Majda I. Majeed AAL, Esmaeel BAM. Effect of Capparis spinosa L. Leaf bud Extract on The hematological and histological changes induced by cyclophosphamide in mice. Research J Pharm. and Tech. 2019; 12(7):3245-3250.
3.    Dale DC, McCarter GC, Crawford J, Lyman GH.  Myelotoxicity and dose intensity of chemotherapy: Reporting practices from randomized clinical trials.  J Natl Compr Cancer Netw. 2003;1:440-54.
4.    Barreto JN, McCullough KB, Ice LL, Smith JA, Antineoplastic agents and the associated myelosuppressive effects: A review. J Pharm Pract. 2014;27:440 -446.
5.    Tagoore DV, Asha K, Mounika UB, Babu KN. An Evaluation of quality of life in patients on concurrent chemo radiotherapy with cisplatin in head and neck cancer- A prospective observational study. Asian J Pharm Res. 2018; 8(1):21-31.
6.    Arunkumar PA, Mukund H, Radheshyam N, Belliyappa MS. Clinical evaluation of cisplatin induced nephrotoxicity characterized by electrolyte disturbances. Asian J Res Pharm Sci. 2011;1(4):100-104.
7.    Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17(1):409-422.
8.    Zahra MA, Taylor A, Mould G, Coles C, Crawford R, and Tan LT. Concurrent weekly cisplatin chemotherapy and radiotherapy in a haemodialysis patient with locally advanced cervix cancer. Clin Oncol. 2008;20(1):6-11.
9.    de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88(8):1199-1206.
10.    Lu Y, Cederbaum A. The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin. Free Radic Biol Med. 2007;43(7):1061-1075.
11.    Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol. 2008;28(3):337-344.
12.    Das B, Yeger H, Baruchel H, Freedman M, Koren G, and Baruchel S. In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. Implications in cancer chemotherapy. Eur J Cancer. 2003;39(17):2556-2565.
13.    Lelieveld P, Van der Vijgh WJ, Veldhuizen RW, Van Velzen D, Van Putten LM, Atassi G, and Danguy A. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol. 1984;20(8):1087-1104.
14.    Su WC, Chang SL, Chen TY, Chen JS, and Tsao CJ. Comparison of in vitro growth-inhibitory activity of carboplatin and cisplatin on leukemic cells and hematopoietic progenitors: the myelosuppressive activity of carboplatin may be greater than its antileukemic effect. Jpn J Clin Oncol. 2000;30(12)562-567.
15.    Trueman P.  Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review. Br J Cancer. 2009;101 Suppl:S15-17.
16.    Ghidini M, Hahne JC, Trevisani F, Panni S, Ratti M, Toppo L, Tomasello G, New developments in the treatment of chemotherapy-induced neutropenia: Focus on balugrastim. Ther Clin Risk Manag. 2016;12:1009-1015.
17.    Arya B, Krishnaveni K, Sambathkumar R. Review on Antioxidant Supplements use in Cancer Chemotherapy. Res. J. Pharmacology & Pharmacodynamics.2020; 12(1):21-24.
18.    Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: Chemistry, bioavailability and effects on health. Nat Prod Rep. 2009;26:1001-1043.
19.    Maheswari TU, Karuppaiya M, Subhagar S, Rahul R. Potent inhibitory action of banana wine polyphenols on colon cancer cells (HCT -15). Research J Pharm and Tech. 2020; 13(11):5387-5390.
20.    Patel RN, Patel UY, Sen DJ. Polyphenol Antioxidants of green tea as free radical scavengers in green heart nanotechnology. Research J Science and Tech. 2010; 2(5): 89-94.
21.    Harris  CS,  Mo  F,  Migahed  L,  Chepelev  L,  Haddad  PS,  Wright JS et al.  Plant phenolics regulate neoplastic cell growth and survival:  a quantitative structure-activity and biochemical analysis.  Can J Physiol  Pharmacol.  2007;85:1124-1138.
22.    Grootveld M, Halliwel MB. 2,3-dihydroxybenzoic  acid is a product of human aspirin metabolism. Biochemical Pharmacology. 1988;37(2):271-280.
23.    Shibumon G, Benny PJ, Sunny K, Cincy G. Antibiotic activity of 2, 3-dihydroxybenzoic acid isolated from Flacourtia inermis fruit against multidrug resistant bacteria. Asian J Pharm and Clin Res. 2011;4(1):126-130.
24.    Parent  MA,  Bellaire  BH,  Murphy  EA,  Roop  RM,  Elzer  PH,  Baldwin CL. Brucella abortus siderophore  2,3-dihydroxybenzoic  acid  (DHBA)  facilitates intracellular survival of the bacteria. Microb Pathog 2002;32:239-248.
25.    Naghibi B, Taghi G, Valiollah H, Ardeshir T, Diana T. The effect of 2,3-dihydroxybenzoic acid and tempol in prevention of vancomycin-induced nephrotoxicity in rats. Toxicol. 2007;232:192-199.
26.    Sinswat P, Wei-jing W, Suhuasha U, Jochen S. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int. 2000;58:2525-2532.
27.    Pujari RR, Bandawane DD. Hepatoprotective activity of gentisic acid on 5-fluorouracil-induced hepatotoxicity in wistar rats Turk J Pharm Sci. 2021;18(3):332-338.
28.    Pujari RR, Vyawahare NS, Thakurdesaii PA. Protective effects of Phoenix dactylifera against oxidative stress and neuronal damage induced by global cerebral ischemia in rats. Biomedicine & Aging Pathology.  2013;3(2):75-81.
29.    Pujari RR, Bandawane DD. Ameliorative effects of Gentisic acid on carboplatin induced hematological toxicities in Wistar Rats. Int J of PharmTech Res. 2019;12(3):22-30.
30.    Raghuramulu N. Madharan N. Kalyansundaram S. A manual of laboratory techniques. Hyderabad: Silver prints. 1983;78:257-8.
31.    Dacie J, Lewis S. Practical Hematology. NewYork, NY: Churchill-Lingstone Edinburgh 1984, 84-86.
32.    Varley H. Practical Clinical Biochemistry (4th ed.). New Delhi: CBC Publisher and distributor 2005.
33.    Samuel KM. Notes on clinical lab techniques. Madras: MGK Iyyer and Sons Publishers 1986,168.
34.    Repetto L. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients:  an observational retrospective survey. Crit Rev Oncol Hematol. 2009;72:170-179.
35.    Woloschuk DMM, Pruemer JM, Cluxton RJ. Carboplatin: a new cisplatin analog. Drug Intelligence and Clinical Pharmacy 1988;22 (11);843-849.
36.    Nayak S, Dixit VK. Effect of Mucuna pruriens seed extracts on drug induced myelosuppression test using albino rats. Research J Pharm and Tech. 2008; 1(3):204-206.
37.    Siddik ZH, Boxall FE, Harrap KR. Haematological toxicity of carboplatin in rats. Br J Cancer. 1987;55:375-379.
38.    Barreto  JN,  McCullough  KB,  Ice  LL,  Smith  JA.  Antineoplastic agents and the associated myelosuppressive effects:  A  review.  J  Pharm Pract . 2014;27: 440-446.
39.    Yessentayeva SE, Kaibullayev BA, Nurzhanov AK, Zhakenova ZK, Sarsenbayeava GE, Turasheva GB, Ilyanova ZT. Methods of treatment of anemia associated with antitumor cytostatic therapy in cancer patients in real clinical practice, based on the results of a retrospective analysis. Research J Pharm and Tech. 2018; 11(9):3833-3840.
40.    Saarto  T,  Blomqvist  C,  Rissanen  P,  Auvinen  A,  Elomaa  I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer. 1997;75: 301-305.
41.    Liu RH. Potential synergism of phytochemicals in cancer prevention: mechanisms of action. J Nutr. 2004;134:3479S-85S.
42.    Kukreja A, Wadhwa N, Tiwari A. Therapeutic role of natural agents in beta-thalassemia: A review. J Pharm Res. 2013;6:954-9.
43.    Khynriam D, Prasad SB. Hematotoxicity and blood glutathione levels after cisplatin treatment of tumor-bearing mice. Cell Biol Toxicol. 2001;17(6):357-70.
44.    Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14:636-643.
45.    Huang A, Ma M, Jin B, Han B. Chemotherapy-induced leukopenia as a prognostic factor in patients with metastatic non-small cell lung cancer treated with platinum-based chemotherapy. Int J Clin Exp Med. 2016;9:5241-5248.
46.    Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;4(2):18-24.
47.    Chandanashree KS, Jacob J, Srivatsa S, Gideon S, George P. Utilization study of antibiotics in febrile neutropenic cancer patients with bacteraemia. Research J Pharm and Tech. 2020; 13(8):3765-3770.
48.    Oguz A, Karadeniz C, Ckitak EC, Cil V. Which one is a risk factor for chemotherapy induced febrile neutropenia in childhood solid tumors: Early lymphopenia or monocytopenia. Pediatr Hematol Oncol. 2006;23(2):143–151.
49.    Sugavasi R, Senthil KS, Kanchanalatha G, Ravi M, Madhankumar S. Effect of Ginkgo biloba extract on hematological and biochemical alterations in fluoride toxicity in Wistar rats. Research J Pharm and Tech. 2019; 12(8):3915-3918.
50.    Taha Nazir Mazhar Mustafa Habib-Ur-Rehman Owais Omar. Basopenia induction by vinorelbine alone and in combination with doxorubicin and cisplatin in cancer patients. Gomal University Journal of Research. 2011;27(1):1-6.
51.    Kondo M, Oshita F, Kato Y, Yamada K, Nomura I, Noda K. Early monocytopenia after chemotherapy as a risk factor for neutropenia. Am J Clin Oncol. 1999;22:103-105.
52.    Graziano JH, Miller DR, Grady RW, Cerami A. Inhibition of membrane peroxidation in thalassaemic erythrocytes by 2,3-dihydroxybenzoic acid. British Journal of Haematology. 1976;32:351–356.
53.    Markman M, Zanotti K, Kulp B, Peterson G, Markman M. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hyper- sensitivity. Gynecol Oncol. 2003;89(3):514-516.
54.    Iuliano F, Santoro M, Iuliano E, Luci M, Pomillo A, Perricelli A. Eltrombopag low doses as prophylaxis of chemotherapy-induced thrombocytopenia (CIT) in cancer patients treated with platinum based chemotherapy. Annals Oncol. 2016;27(4):122-123.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available